Kawasaki disease patients homozygous for the rs12252-c variant of interferon-induced transmembrane protein-3 are significantly more likely to develop coronary artery lesions

Molecular Genetics and Genomic Medicine

Volumn 2, Issue 4, 2014, Pages 356-361

  Bowles, Neil E ^a   Arrington, Cammon B ^a   Hirono, Keiichi ^b   Nakamura, Tsuneyuki ^c   Ngo, Long ^d   Wee, Yin Shen ^a   Ichida, Fukiko ^b   Weis, John H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983206196     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.79     Document Type: Letter

References (33)

1. Arrington, C. B., S. B. Bleyl, N. Matsunami, G. D. Bonnell, B. E. Otterud, D. C. Nielsen, et al. 2012. Exome analysis of a family with pleiotropic congenital heart disease. Circ. Cardiovasc. Genet. 5:175–182.
2. Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M. Feeley, et al. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243–1254.
3. Burgner, D., and A. Harnden. 2005. Kawasaki disease: what is the epidemiology telling us about the etiology? Int. J. Infect. Dis. 9:185–194.
4. Chang, C. J., H. C. Kuo, J. S. Chang, J. K. Lee, F. J. Tsai, C. C. Khor, et al. 2013. Replication and meta-analysis of GWAS identified susceptibility loci in kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. PLoS One 8:e72037.
5. Everitt, A. R., S. Clare, T. Pertel, S. P. John, R. S. Wash, S. E. Smith, et al. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519–523.
6. Feeley, E. M., J. S. Sims, S. P. John, C. R. Chin, T. Pertel, L. M. Chen, et al. 2011. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 7:e1002337.
7. Fujita, Y., Y. Nakamura, K. Sakata, N. Hara, M. Kobayashi, M. Nagai, et al. 1989. Kawasaki disease in families. Pediatrics 84:666–669.
8. Holman, R. C., E. D. Belay, K. Y. Christensen, A. M. Folkema, C. A. Steiner, and L. B. Schonberger. 2010a. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr. Infect. Dis. J. 29:483–488.
9. Holman, R. C., K. Y. Christensen, E. D. Belay, C. A. Steiner, P. V. Effler, J. Miyamura, et al. 2010b. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med. J. 69:194–197.
10. Hsieh, Y. Y., Y. J. Lin, C. C. Chang, D. Y. Chen, C. M. Hsu, Y. K. Wang, et al. 2010. Human lymphocyte antigen B-associated transcript 2, 3, and 5 polymorphisms and haplotypes are associated with susceptibility of Kawasaki disease and coronary artery aneurysm. J. Clin. Lab. Anal. 24:262–268.
11. Huang, I. C., C. C. Bailey, J. L. Weyer, S. R. Radoshitzky, M. M. Becker, J. J. Chiang, et al. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7:e1001258.
12. Jiang, D., J. M. Weidner, M. Qing, X. B. Pan, H. Guo, C. Xu, et al. 2010. Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J. Virol. 84:8332–8341.
13. Kato, H., T. Sugimura, T. Akagi, N. Sato, K. Hashino, Y. Maeno, et al. 1996. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation 94:1379–1385.
14. Kawasaki, T. 1979. Clinical signs and symptoms of mucocutaneous lymph node syndrome (Kawasaki disease). Jpn. J. Med. Sci. Biol. 32:237–238.
15. Kawasaki, T., F. Kosaki, S. Okawa, I. Shigematsu, and H. Yanagawa. 1974. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54:271–276.
16. Khor, C. C., S. Davila, W. B. Breunis, Y. C. Lee, C. Shimizu, V. J. Wright, et al. 2011. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat. Genet. 43:1241–1246.
17. Kuo, H. C., Y. W. Hsu, C. M. Wu, S. H. Chen, K. S. Hung, W. P. Chang, et al. 2013. A replication study for association of ITPKC and CASP3 two-locus analysis in IVIG unresponsiveness and coronary artery lesion in Kawasaki disease. PLoS One 8:e69685.
18. Lehner, B., J. I. Semple, S. E. Brown, D. Counsell, R. D. Campbell, and C. M. Sanderson. 2004. Analysis of a high-throughput yeast two-hybrid system and its use to predict the function of intracellular proteins encoded within the human MHC class III region. Genomics 83:153–167.
19. Lu, J., Q. Pan, L. Rong, S. L. Liu, and C. Liang. 2011. The IFITM proteins inhibit HIV-1 infection. J. Virol. 85:2126–2137.
20. Martin, B. R., C. Wang, A. Adibekian, S. E. Tully, and B. F. Cravatt. 2012. Global profiling of dynamic protein palmitoylation. Nat. Methods 9:84–89.
21. Nakamura, Y., M. Yashiro, R. Uehara, A. Sadakane, S. Tsuboi, Y. Aoyama, et al. 2012. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. J. Epidemiol. 22:216–221.
22. Ogata, S., A. H. Tremoulet, Y. Sato, K. Ueda, C. Shimizu, X. Sun, et al. 2013. Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. Int. J. Cardiol. 168:3825–3828.
23. Onouchi, Y. 2012. Genetics of Kawasaki disease: what we know and don’t know. Circ. J. 76:1581–1586.
24. Onouchi, Y., K. Ozaki, J. C. Buns, C. Shimizu, H. Hamada, T. Honda, et al. 2010. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum. Mol. Genet. 19:2898–2906.
25. Onouchi, Y., K. Ozaki, J. C. Burns, C. Shimizu, M. Terai, H. Hamada, et al. 2012. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat. Genet. 44:517–521.
26. Rodriguez, S., T. R. Gaunt, and I. N. Day. 2009. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169:505–514.
27. Saji, T., and Y. Kemmotsu. 2006. Infliximab for Kawasaki syndrome. J. Pediatr. 149:426.
28. Shulman, S. T., J. De Inocencio, and R. Hirsch. 1995. Kawasaki disease. Pediatr. Clin. North Am. 42:1205–1222.
29. Smith, R. A., J. Young, J. J. Weis, and J. H. Weis. 2006. Expression of the mouse fragilis gene products in immune cells and association with receptor signaling complexes. Genes Immun. 7:113–121.
30. Uehara, R., M. Yashiro, Y. Nakamura, and H. Yanagawa. 2004. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch. Pediatr. Adolesc. Med. 158:1166–1169.
31. Wang, C. L., Y. T. Wu, C. A. Liu, H. C. Kuo, and K. D. Yang. 2005. Kawasaki disease: infection, immunity and genetics. Pediatr. Infect. Dis. J. 24:998–1004.
32. Weidner, J. M., D. Jiang, X. B. Pan, J. Chang, T. M. Block, and J. T. Guo. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84:12646–12657.
33. Zhang, Y. H., Y. Zhao, N. Li, Y. C. Peng, E. Giannoulatou, R. H. Jin, et al. 2013. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat. Commun. 4:1418.